Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067267 | 0.86 | MAPT (0.46) | ALDH1A1MAPTGAATSHR | |
| SCHEMBL10067272 | 0.85 | MAPT (0.48) | ALDH1A1MAPTGAAPOLBTSHR | |
| SCHEMBL10067302 | 0.85 | MAPT (0.48) | ALDH1A1MAPTGAAPOLBTSHR | |
| SCHEMBL10067264 | 0.84 | PDE4A (0.45) | KMT2AALDH1A1MEN1TSHR | |
| SCHEMBL10067276 | 0.83 | KMT2A (0.52) | KMT2AALDH1A1MAPTGAAMEN1 | |
| SCHEMBL10067310 | 0.83 | KMT2A (0.48) | KMT2AMAPTGAAMEN1 | |
| SCHEMBL10067293 | 0.82 | ALDH1A1 (0.52) | KMT2AALDH1A1KDM4EMAPTGAA | |
| SCHEMBL10067292 | 0.82 | MAPT (0.52) | KMT2AALDH1A1KDM4EGSK3BMAPT | |
| SCHEMBL14091498 | 0.81 | PDE5A (0.49) | — | |
| SCHEMBL10067280 | 0.77 | IDO1 (0.47) | KMT2AALDH1A1KDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692113-B1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2005047266-A9 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | KMT2A 396/4885STAT3 1924/4885TBXAS1 1893/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | KMT2A 362/4885STAT3 1936/4885TBXAS1 2028/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | KMT2A 396/4885STAT3 1924/4885TBXAS1 1893/4885 |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | KMT2A 377/4885STAT3 101/4885TBXAS1 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.